Document:

Exhibit 10(vii)

 

 

 

 

 

 

Note Purchase Agreement

 

By and Among

 

Electromedical Technologies,
Inc.

 

And

 

JR-HD Enterprises III, LLC

 

Dated as of November 3,
2020

 

 

 

 

     

     

    

 

TABLE OF CONTENTS

 

	Article I.   	DEFINITIONS	1
	 	 
	Section 1.01   	Definitions.	1
	Section 1.02   	Interpretive Provisions.	2
	 	 
	Article II.   	PURCHASE AND SALE	3
	 	 
	Section 2.01   	Purchase and Sale.	3
	Section 2.02   	Deliverables at Closing.	3
	Section 2.03   	Closing.	3
	Section 2.04   	Use of Proceeds.	3
	 	 
	Article III.   	REPRESENTATIONS AND WARRANTIES
OF THE COMPANY	3
	 	 
	Section 3.01   	Authorization of Transactions.	3
	Section 3.02   	Governmental Approvals; Non-contravention.	4
	Section 3.03   	Brokers.	4
	 	 
	Article IV.   	REPRESENTATIONS AND WARRANTIES
OF BUYER	4
	 	 
	Section 4.01   	Authorization of Transactions.	4
	Section 4.02   	Governmental Approvals; Non-contravention.	4
	Section 4.03   	Investment Representations.	5
	Section 4.04   	Brokers.	6
	 	 
	Article V.   	INDEMNIFICATION	6
	 	 
	Section 5.01   	General Indemnification.	6
	Section 5.02  	Procedures for Indemnification.	6
	Section 5.03   	Payment.	6
	Section 5.04   	Effect of Knowledge on Indemnification.	6
	 	 
	Article VI.   	MISCELLANEOUS	7
	 	 
	Section 6.01   	Notices.	7
	Section 6.02   	Attorneys’ Fees	7
	Section 6.03   	Amendments; No Waivers; No
Third-Party Beneficiaries.	7
	Section 6.04   	Expenses.	8
	Section 6.05   	Further Assurances.	8
	Section 6.06   	Successors and Assigns; Benefit.	8
	Section 6.07   	Governing Law; Etc.	8
	Section 6.08   	Survival.	9
	Section 6.09   	Resolution of Disputes.	9
	Section 6.10   	Severability.	10
	Section 6.11   	Entire Agreement.	10
	Section 6.12   	Specific Performance.	10
	Section 6.13   	Construction.	10
	Section 6.14   	Counterparts.	10

 

     

     

    

 

NOTE PURCHASE AGREEMENT

 

This Note Purchase
Agreement (together with all exhibits hereto, this “Agreement”) is entered into as of November 3, 2020 (the “Closing
Date”), by and among Electromedical Technologies, Inc., a Delaware corporation (the “Company”) and JR-HD Enterprises
III, LLC, a Delaware limited liability company (“Buyer”). The Company and the Buyer may be collectively referred to
herein as the “Parties” and individually as a “Party”.

 

WHEREAS, the Company
desires to issue and sell to the Buyer a convertible promissory note in the aggregate principal amount of $244,852.94 and in the
form as attached hereto as Exhibit A (the “Note”) on the terms set forth herein and the Buyer wishes to purchase the
Note on the terms and conditions provided for herein;

 

NOW, THEREFORE, in
consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

Article I.                 
DEFINITIONS

 

Section 1.01        Definitions.
In addition to the terms defined elsewhere in this Agreement, the following terms, as used herein, have the following
meanings:

 

		(a)	“Affiliate” means, with respect to a specified Person, any other Person that directly
or indirectly Controls, is Controlled by or is under common Control with, the specified Person.

 

		(b)	“Business Day” means any day except Saturday, Sunday and any legal holiday or a day
on which banking institutions in Delaware generally are authorized or required by Law or other governmental actions to close.

 

		(c)	“Contract” means any contract, commitment, understanding or agreement (whether oral
or written).

 

		(d)	“Common Stock” mean shares of common stock, par value $0.00001 per share, of the Company.

 

		(e)	“Control” means (a) the possession, directly or indirectly, of the power to vote 10%
or more of the securities or other equity interests of a Person having ordinary voting power, (b) the possession, directly or indirectly,
of the power to direct or cause the direction of the management and policies of a Person, by contractor otherwise, or (c) being
a director, officer, executor, trustee or fiduciary (or their equivalents) of a Person or a Person that controls such Person.

 

		(f)	“Governmental Entity” means any federal, state, municipal, local or foreign government
and any court, tribunal, arbitral body, administrative agency, department, subdivision, entity, commission or other governmental,
government appointed, quasi-governmental or regulatory authority, reporting entity or agency, domestic, foreign or supranational.

 

		(g)	“Law” means any applicable foreign, federal, state or local law (including common law),
statute, treaty, rule, directive, regulation, ordinances and similar provisions having the force or effect of law or an Order of
any Governmental Entity.

 

    1 

     

    

 

		(h)	“Liabilities” means liabilities, obligations or responsibilities of any nature whatsoever,
whether direct or indirect, matured or un-matured, fixed or unfixed, known or unknown, asserted or un asserted, choate or inchoate,
liquidated or unliquidated, secured or unsecured, absolute, contingent or otherwise, including any direct or indirect indebtedness,
guaranty, endorsement, claim, loss, damage, deficiency, cost or expense.

 

		(i)	“Lien” means, with respect to any property or asset, any lien, security interest, mortgage,
pledge, charge, claim, lease, agreement, right of first refusal, option, limitation on transfer or use or assignment or licensing,
restrictive easement, charge or any other restriction of any kind, and any conditional sale or voting agreement or proxy, and including
any restriction on the ownership, use, voting, transfer, possession, receipt of income or other exercise of any attributes of ownership,
in respect of such property or asset, and any agreement to give any of the foregoing.

 

		(j)	“Losses” means any losses, damages, deficiencies, Liabilities, assessments, fines,
penalties, judgments, actions, claims, costs, disbursements, fees, expenses or settlements of any kind or nature, including legal,
accounting and other professional fees and expenses.

 

		(k)	“Order” means any judgment, writ, decree, determination, award, compliance agreement,
settlement agreement, injunction, ruling, charge, judicial or administrative order, determination or other restriction of any Governmental
Entity or arbitrator.

 

		(l)	“Person” means a natural person, a corporation, a limited liability company, a partnership,
an association, a trust or any other entity or organization, including a government or political subdivision or any agency or instrumentality
thereof.

 

		(m)	“Securities Act” means the United States Securities Act of 1933, as amended, and the
rules and regulation promulgated thereunder.

 

		(n)	“Transactions” means the purchase and sale of the Note and the other transactions contemplated
under the Transaction Documents.

 

		(o)	“Transaction Documents” means this Agreement, the Note and any other agreement, document,
certificate or writing delivered or to be delivered in connection with this Agreement and any other document related to the Transactions
related to the forgoing, including, without limitations, those delivered at the Closing.

 

Section 1.02        Interpretive
Provisions. Unless the express context otherwise requires, the words “hereof,” “herein,” and
 “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole
and not to any particular provision of this Agreement; terms defined in the singular shall have a comparable meaning when
used in the plural, and vice versa; the terms “Dollars” and “$” mean United States Dollars, unless
otherwise specified herein; references herein to a specific Section, Subsection, Recital or Exhibit shall refer,
respectively, to Sections, Subsections, Recitals or Exhibits of this Agreement; wherever the word
 “include,” “includes,” or “including” is used in this Agreement, it shall be deemed to be
followed by the words “without limitation”; references herein to any gender shall include each other gender;
references herein to any Person shall include such Person’s heirs, executors, personal representatives, administrators,
successors and assigns; provided, however, that nothing contained in this Section 1.02 is intended to authorize any
assignment or transfer not otherwise permitted by this Agreement; references herein to a Person in a particular capacity or
capacities shall exclude such Person in any other capacity; references herein to any contract or agreement (including this
Agreement) mean such contract or agreement as amended, supplemented or modified from time to time in accordance with the
terms thereof; with respect to the determination of any period of time, the word “from” means “from and
including” and the words “to” and “until” each means “to but excluding”; references
herein to any Law or any license mean such Law or license as amended, modified, codified, reenacted, supplemented or
superseded in whole or in part, and in effect from time to time; and references herein to any Law shall be deemed also to
refer to all rules and regulations promulgated thereunder.

 

    2 

     

    

 

Article II.             
PURCHASE AND SALE

 

Section 2.01       
Purchase and Sale. Subject to the terms and conditions of this Agreement, at the Closing (as defined below), the
Company shall issue and sell to Buyer a Note in the aggregate principal amount of $244,852.94, for a purchase price of $225,000.00
(the “Purchase Price”), reflecting a $19,852.94 original issue discount.

 

Section 2.02       
Deliverables at Closing. At the Closing (as defined below), Buyer shall deliver the Purchase Price to the Company
via a check payable to the Company or wire transfer pursuant to the wire transfer instructions as provided by the Company to Buyer,
and the Company shall issue to Buyer the Note.

 

Section 2.03       
Closing. On the terms set forth herein, the closing of the Transactions (the “Closing”) shall take place
by conference call and electronic communication (i.e., emails/pdf) or facsimile, with exchange of original signatures to follow
by mail, on the date hereof and effective as of 11:59 p.m. Eastern time, on such date.

 

Section 2.04       
Use of Proceeds. The Company covenants and agrees that it shall utilize the Purchase Price for working capital purposes.

 

Article III.          
REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents
and warrants to Buyer that the following representations and warranties contained in this Article III are true and correct as of
the Closing Date:

 

Section 3.01       
Authorization of Transactions. The Company is a corporation duly authorized and in good standing in the State of
Delaware and has the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and to
perform its obligations hereunder and thereunder. The execution, delivery and performance by the Company of the applicable Transaction
Documents and the consummation of the Transactions have been duly and validly authorized by all requisite action on the part of
the Company. The Transaction Documents to which the Company is a party have been duly and validly executed and delivered by The
Company. Each Transaction Document to which the Company is a party constitutes the valid and legally binding obligation of the
Company, enforceable against the Company in accordance with its terms and conditions, except to the extent enforcement thereof
may be limited by applicable bankruptcy, insolvency or other Laws affecting the enforcement of creditors’ rights or by the
principles governing the availability of equitable remedies.

 

    3 

     

    

 

Section 3.02       
Governmental Approvals; Non-contravention. 

 

		(a)	No consent, Order, action or non-action of, or filing, notification, declaration or registration
with, any Governmental Entity or Person is necessary for the execution, delivery or performance by the Company of this Agreement
or any other Transaction Document to which the Company is a party.

 

		(b)	The execution, delivery and performance by the Company of the Transaction Documents to which the
Company is a party, and the consummation by the Company of the Transactions, do not (i) violate or conflict with any Law or Order
to which the Company or the Note may be subject, (ii) constitute a violation or breach of, be in conflict with, constitute or create
(with or without due notice or lapse of time or both) a default (or give rise to any right of termination, modification, cancellation
or acceleration) of any obligation under any Contract to which the Company is a party or to which the Company or the Note are subject
or by which the Company’s properties, assets or rights are bound or (iii) result in the creation or imposition of any Lien
upon any of the rights, properties or assets of the Company or on the Note.

 

Section 3.03       
Brokers. The Company has not engaged, or caused to be incurred any Liability or obligation to, any investment banker,
finder, broker or sales agent or any other Person in connection with the origin, negotiation, execution, delivery or performance
of the Transaction Documents to which it is a party, or the Transactions.

 

Article IV.           
REPRESENTATIONS AND WARRANTIES OF BUYER

 

Buyer represents and
warrants to the Company that the following statements contained in this Article IV are true and correct as of the Closing Date:

 

Section 4.01       
Authorization of Transactions. Buyer is a limited liability company, duly qualified under the laws of the State of
Delaware, and has the requisite power and capacity to execute and deliver the Transaction Documents to which it is a party and
to perform its obligations hereunder and thereunder. The execution, delivery and performance by Buyer of the applicable Transaction
Documents and the consummation of the Transactions have been duly and validly authorized by all requisite action on the part of
Buyer. The Transaction Documents to which Buyer is a party have been duly and validly executed and delivered by Buyer. Each Transaction
Document to which Buyer is a party constitutes the valid and legally binding obligation of Buyer, enforceable against Buyer in
accordance with its terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency
or other Laws affecting the enforcement of creditors’ rights or by the principles governing the availability of equitable
remedies.

 

Section 4.02       
Governmental Approvals; Non-contravention.

 

		(a)	No consent, Order, action or non-action of, or filing, notification, declaration or registration
with, any Governmental Entity is necessary for the execution, delivery or performance by Buyer of this Agreement or any other Transaction
Document to which Buyer is a party.

 

		(b)	The execution, delivery and performance by Buyer of the Transaction Documents to which Buyer is
a party, and the consummation by Buyer of the Transactions, do not violate any Laws or Orders to which Buyer is subject or violate,
breach or conflict with any provision of Buyer’s organizational documents.

 

    4 

     

    

 

Section 4.03       
Investment Representations.

 

		(a)	Buyer understands and agrees that the consummation of this Agreement including the delivery of
the Note as contemplated hereby and the shares of Common Stock that may be issued to Buyer pursuant to the Note (the “Shares”
and, together with the Note, collectively, the “Securities”) constitute the offer and sale of securities under the
Securities Act and applicable state statutes and that the Securities are being acquired for Buyer’s own account and not with
a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration
under the Securities Act.

 

		(b)	Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation
D under the Securities Act.

 

		(c)	Buyer understands that the Securities are being offered and sold to Buyer in reliance upon specific
exemptions from the registration requirements of United States federal and state securities Laws and that the Company is relying
upon the truth and accuracy of, and Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of Buyer
to acquire the Securities.

 

		(d)	At no time was Buyer presented with or solicited by any leaflet, newspaper or magazine article,
radio or television advertisement, or any other form of general advertising or solicited or invited to attend a promotional meeting
otherwise than in connection and concurrently with such communicated offer. Buyer is not purchasing the Note acquired by Buyer
hereunder as a result of any “general solicitation” or “general advertising,” as such terms are defined
in Regulation D under the Securities Act, which includes, but is not limited to, any advertisement, article, notice or other communication
regarding the Note acquired by Buyer hereunder published in any newspaper, magazine or similar media or on the internet or broadcast
over television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement.

 

		(e)	Buyer is acquiring the Securities for its own account as principal, not as a nominee or agent,
for investment purposes only, and not with a view to, or for, resale, distribution or fractionalization thereof in whole or in
part and no other person has a direct or indirect beneficial interest in the Securities. Further, Buyer does not have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third
person, with respect to the Securities.

 

		(f)	Buyer, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment.

 

		(g)	Buyer understands that no United States federal or state agency or any other governmental or state
agency has passed on or made recommendations or endorsement of the Securities or the suitability of the investment in the Securities
nor have such authorities passed upon or endorsed the merits of the transactions set forth herein.

 

    5 

     

    

 

Section 4.04       
Brokers. Buyer has not engaged any investment banker, finder, broker or sales agent or any other Person in connection
with the origin, negotiation, execution, delivery or performance of any Transaction Document to which it is a party, or the Transactions.

 

Article V.              
INDEMNIFICATION

 

Section 5.01       
General Indemnification. Each Party (the “Indemnifying Party”) agrees to indemnify, defend and hold harmless
the other Party and such other Party’s Affiliates and each of their respective directors, officers, managers, partners, employees,
agents, equity holders, successors and assigns (each, an “Indemnified Party”), from and against any and all Losses
incurred or suffered by any Indemnified Party arising out of, based upon or resulting from any breach of any representation or
warranty of the Indemnifying Party herein or breach by the Indemnifying Party of, or any failure the Indemnifying Party to perform,
any of the covenants, agreements or obligations contained in or made pursuant to this Agreement or the Transaction Documents by
the Indemnifying Party.

 

Section 5.02       
Procedures for Indemnification. In the event that an Indemnified Party shall incur or suffer any Losses in respect
of which indemnification may be sought under this Article V against the Indemnifying Party, the Indemnified Party shall assert
a claim for indemnification by providing a written notice (the “Notice of Loss”) to the Indemnifying Party stating
the nature and basis of such indemnification. The Notice of Loss shall be provided to the Indemnifying Party as soon as practicable
after the Indemnified Party becomes aware that it has incurred or suffered a Loss.

 

Section 5.03       
Payment. Upon a determination of liability under this Article V the Indemnifying Party shall pay or cause to be paid
to the Indemnified Party the amount so determined within five (5) Business Days after the date of such determination. If there
should be a dispute as to the amount or manner of determination of any indemnity obligation owed under this Agreement, the Indemnifying
Party shall nevertheless pay when due such portion, if any, of the obligation that is not subject to dispute. Upon the payment
in full of any amounts due under this Article V with respect to any claim, the Indemnifying Party shall be subrogated to the rights
of the Indemnified Party against any Person with respect to the subject matter of such claim.

 

Section 5.04       
Effect of Knowledge on Indemnification. The right to indemnification, reimbursement or other remedy based upon any
representations, warranties, covenants and obligations set forth in this Agreement shall not be affected by any investigation conducted
with respect to, or any knowledge acquired (or capable of being acquired) at any time, whether before or after the execution and
delivery of this Agreement, with respect to the accuracy or inaccuracy of or compliance with any such representation, warranty,
covenant or obligation. The waiver of any condition based upon the accuracy of any representation or warranty, or on the performance
of or compliance with any covenant or obligation, shall not affect the right to indemnification, reimbursement or other remedy
based upon such representations, warranties, covenants or obligations.

 

    6 

     

    

 

Article VI.           
MISCELLANEOUS

 

Section 6.01       
Notices. 

 

		(a)	Any notice or other communications required or permitted hereunder shall be in writing and shall
be sufficiently given if personally delivered to it or sent by email, overnight courier or registered mail or certified mail, postage
prepaid, addressed as follows:

 

if to the Company,
to:

 

Electromedical Technologies, Inc. 

Attn: Matthew Wolfson

16561 N. 92nd Street, Suite 101

Scottsdale, AZ 85260

Email: ceo@electromedtech.com

 

If
to the Buyer, to:

 

JR-HD Enterprises
III, LLC

Attn: Jeff
Ramson

150 East
58th Street, 20th Floor

New York,
NY 10155

Email: Jramson@pcgadvisory.com

 

With a copy, which
shall not constitute notice, to:

 

Anthony L.G.,
PLLC

Attn: John
Cacomanolis

625 N. Flagler
Drive, Suite 600

West Palm
Beach, FL 33401

Email: jcacomanolis@anthonypllc.com

 

		(b)	Any Party may change its address for notices hereunder upon notice to each other Party in the manner
for giving notices hereunder.

 

		(c)	Any notice hereunder shall be deemed to have been given (i) upon receipt, if personally delivered,
(ii) on the day after dispatch, if sent by overnight courier, (iii) upon dispatch, if transmitted by email with return receipt
requested and received and (iv) three (3) days after mailing, if sent by registered or certified mail.

 

Section 6.02       
Attorneys’ Fees. In the event that any Party institutes any action or suit to enforce this Agreement or to
secure relief from any default hereunder or breach hereof, the prevailing Party shall be reimbursed by the losing Party for all
costs, including reasonable attorney’s fees, incurred in connection therewith and in enforcing or collecting any judgment
rendered therein.

 

Section 6.03       
Amendments; No Waivers; No Third-Party Beneficiaries.

 

		(a)	This Agreement may be amended, modified, superseded, terminated or cancelled, and any of the terms,
covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by both of the
Parties.

 

    7 

     

    

 

		(b)	Every right and remedy provided herein shall be cumulative with every other right and remedy, whether
conferred herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any Party of the performance
of any obligation by another Party shall be construed as a waiver of the same or any other default then, theretofore, or thereafter
occurring or existing.

 

		(c)	Neither any failure or delay in exercising any right or remedy hereunder or in requiring satisfaction
of any condition herein nor any course of dealing shall constitute a waiver of or prevent any Party from enforcing any right or
remedy or from requiring satisfaction of any condition. No notice to or demand on a Party waives or otherwise affects any obligation
of that Party or impairs any right of the Party giving such notice or making such demand, including any right to take any action
without notice or demand not otherwise required by this Agreement. No exercise of any right or remedy with respect to a breach
of this Agreement shall preclude exercise of any other right or remedy, as appropriate to make the aggrieved Party whole with respect
to such breach, or subsequent exercise of any right or remedy with respect to any other breach.

 

		(d)	Notwithstanding anything else contained herein, no Party shall seek, nor shall any Party be liable
for, consequential, punitive or exemplary damages, under any tort, contract, equity, or other legal theory, with respect to any
breach (or alleged breach) of this Agreement or any provision hereof or any matter otherwise relating hereto or arising in connection
herewith.

 

Section 6.04       
Expenses. Unless otherwise contemplated or stipulated by a Transaction Document, all costs and expenses incurred
in connection with this Agreement shall be paid by the Party incurring such cost or expense.

 

Section 6.05       
Further Assurances. Following the Closing, each Party shall execute and deliver such documents and other papers and
take such further action as may be reasonably required to carry out the provisions of the Transaction Documents.

 

Section 6.06       
Successors and Assigns; Benefit. The provisions of this Agreement shall be binding upon and inure to the benefit
of the Parties and their respective successors and assigns. No Party may assign, delegate or otherwise transfer any of its rights
or obligations under this Agreement without the written consent of the other Party. Other than as specifically set forth herein,
including in Article V, nothing in this Agreement shall confer on any Person other than the Parties, and their respective successors
and assigns, any rights, remedies, obligations, or Liabilities under or by reason of this Agreement.

 

Section 6.07       
Governing Law; Etc.

 

		(a)	This Agreement, and all matters based upon, arising out of or relating in any way to the Transactions
or the Transaction Documents, including all disputes, claims or causes of action arising out of or relating to the Transactions
or the Transaction Documents as well as the interpretation, construction, performance and enforcement of the Transaction Documents,
shall be governed by the laws of the United States and the State of Delaware, without regard to any jurisdiction’s conflict-of-laws
principles.

 

    8 

     

    

 

		(b)	SUBJECT TO Section 6.09, ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS
AGREEMENT, THE OTHER TRANSACTION DOCUMENTS OR THE CONTEMPLATED TRANSACTIONS SHALL BE INSTITUTED SOLELY IN THE FEDERAL COURTS OF
THE UNITED STATES OF AMERICA OR THE COURTS OF THE STATE OF NEW YORK, IN EACH CASE LOCATED IN NEW YORK CITY, NEW YORK, AND EACH
PARTY IRREVOCABLY SUBMITS TO THE PERSONAL JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING. THE PARTIES IRREVOCABLY
AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY
WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS
BEEN BROUGHT IN AN INCONVENIENT FORUM.

 

		(c)	EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT
MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS, THE PERFORMANCE THEREOF OR THE FINANCINGS CONTEMPLATED THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).
EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES
THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS
AND CERTIFICATIONS IN THIS Section 6.07(c).

 

		(d)	Each of the Parties acknowledge that each has been represented in connection with the signing of
this waiver by independent legal counsel selected by the respective Party and that such Party has discussed the legal consequences
and import of this waiver with legal counsel. Each of the Parties further acknowledge that each has read and understands the meaning
of this waiver and grants this waiver knowingly, voluntarily, without duress and only after consideration of the consequences of
this waiver with legal counsel.

 

Section 6.08       
Survival. The representations and warranties in this Agreement shall survive the Closing
for a period of 12 months from the Closing Date, and no claim for indemnification may be made after such time. All covenants and
agreements in this Agreement will survive until fully performed; provided, however, that, nothing herein shall prevent a Party
from making any claim hereunder, or relieve any other Party from any liability hereunder, after such time for any breach thereof.

 

Section 6.09       
Resolution of Disputes. Except as otherwise provided herein, all controversies, disputes or actions between the Parties
arising out of the Transactions or this Agreement, including their respective Affiliates, owners, officers, directors, agents and
employees, arising from or relating to this Agreement shall on demand of either party be submitted for arbitration to in accordance
with the rules and regulations of the American Arbitration Association. The arbitration shall be conducted by one arbitrator jointly
selected by each Party who is a party to the Dispute, provided, however, that if such Parties are unable to agree on the identity
of the arbitrator within 10 Business Days of commencement of efforts to do so, each Party who is a party to the Dispute shall select
one arbitrator and the arbitrators so selected shall select a final arbitrator, and the final arbitrator shall conduct the arbitration
alone. The Parties agree that, in connection with any such arbitration proceeding, each shall submit or file any claim which would
constitute a compulsory counterclaim (as defined by Rule 13 of the Federal Rules of Civil Procedures) within the same proceeding
as the claim to which it relates. Any such claim which is not submitted or filed in such proceeding shall be barred. The arbitrator
shall be instructed to use every reasonable effort to perform its services within seven days of request, and, in any case, as soon
as practicable. The Parties agree to be bound by the provisions of any limitation on the period of time by which claims must be
brought under Delaware law or any applicable federal law. The arbitrator(s) shall have the right to award the relief which he or
she deems proper, consistent with the terms of this Agreement, including compensatory damages (with interest on unpaid amounts
from due date), injunctive relief, specific performance, legal damages and costs. The award and decision of the arbitrator(s) shall
be conclusive and binding on all Parties, and judgment upon the award may be entered in any court of competent jurisdiction. Any
right to contest the validity or enforceability of this award shall be governed exclusively by the United States Arbitration Act.
The arbitration shall be conducted in New York City, New York. The provisions of this Section 6.09 shall continue in full force
and effect subsequent to and notwithstanding the expiration or termination of this Agreement.

 

    9 

     

    

 

Section 6.10       
Severability. If any provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of
law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect
so long as the economic or legal substance of the Transactions is not affected in any manner adverse to any Party. Upon such determination
that any provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that the
Transactions are fulfilled to the extent possible.

 

Section 6.11       
Entire Agreement. The Transaction Documents constitute the entire agreement between the Parties with respect to the
subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the Parties
with respect to the subject matter hereof and thereof.

 

Section 6.12       
Specific Performance. Each Party agrees that irreparable damage would occur if any provision of this Agreement were
not performed in accordance with the terms hereof and that each Party shall be entitled to seek specific performance of the terms
hereof in addition to any other remedy at law or in equity.

 

Section 6.13       
Construction. The table of contents and headings contained in this Agreement are for reference purposes only and
will not affect in any way the meaning or interpretation of this Agreement. In the event of a conflict between language or amounts
contained in the body of this Agreement and language or amounts contained in the Exhibits attached hereto, the language or amounts
in the body of the Agreement shall control. References to Articles or Sections shall refer to those portions of this Agreement.
The use of the terms “hereunder,” “hereof,” “hereto” and words of similar import shall refer
to this Agreement as a whole and not to any particular Article, Section or clause of or Exhibit to this Agreement.

 

Section 6.14       
Counterparts. This Agreement may be executed in two or more counterparts, all of which shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each of the Parties and delivered to the other
Parties, it being understood that each Party need not sign the same counterpart. A facsimile copy or electronic transmission of
a signature page shall be deemed to be an original signature page.

 

[Signature page follows]

 

    10 

     

    

 

IN WITNESS WHEREOF,
the Parties have caused this Agreement to be duly executed as of the Closing Date.

 

	 	Electromedical Technologies, Inc.
	 	 	 
	 	 	 
	 	By:	 
	 	Name:	Matthew Wolfson
	 	Title:	Chief Executive Officer
	 	 	 
	 	 	 
	 	JR-HD Enterprises III, LLC
	 	 	 
	 	 	 
	 	By:	 
	 	Name:	Jeff Ramson
	 	Title:	Manager

   

    11 

     

    

 

Exhibit A

Convertible Promissory Note

 

(Attached)

 

    12Exhibit 10(viii)

 

Settlement
Agreement & Release

 

This Settlement Agreement
 & Release ("Agreement"), dated this 9th day of November, 2020 is by and between Electromedical Technologies,
Inc. a Delaware Corporation having a principal place of business at 16561 N 92nd Street Ste. 101, Scottsdale AZ 85260 ("EMED"),
and Iakovos Tsakalidis ("TSAKALIDIS"). Both EMED and TSAKALIDIS may be collectively referred to as the “Parties.”

 

RECITALS:

 

Whereas,
TSAKALIDIS historically provided financing to EMED in order to aid EMED
in its operations. As security for TSAKALIDIS’ loans to EMED, EMED agreed to issue TSAKALIDIS 87,849 registered common shares.
The shares were issued and were registered in EMED’s Form S-1 Registration Statement made effective by the Securities and
Exchange Commission on August 6, 2020.

 

WHEREAS,
As of the date hereof, EMED is in arrears in its payment obligations to TSAKALIDIS in the amount
of $36,413. 

 

WHEREAS,
EMED and TSAKALIDIS have held good faith communications concerning amounts due through NOVEMBER
9, 2020, and have come to an agreement whereby EMED will pay TSAKALIDIS $36,413 on November 9, 2020, and TSAKALIDIS agrees to cancel
and return to EMED’s treasury the 87,849 shares of registered common stock issued to TSAKALIDIS as security for his loans
to EMED.

 

NOW
THEREFORE, in consideration for the mutual promises and covenants contained
herein, the sufficiency of which is hereby acknowledged, EMED and TSAKALIDIS hereto agree as follows: 

 

		Section 1.	Incorporation of the RECITALS clauses.

 

1.1.         EMED and TSAKALIDIS acknowledge that all of the representations set forth in the RECITALS clauses of this Agreement are
incorporated herein by reference and made a material part of this Agreement with the same force and effect as if more fully set
forth here at. EMED and TSAKALIDIS agree to waive any rule of contract construction or legal presumption that would prohibit any
court of competent jurisdiction from construing or enforcing this Agreement based upon the contents of the RECITALS above.

 

    Page 1 of 3

     

    

 

		Section 2.	Settlement Payment, Document Delivery; Release of All
Claims.

 

2.1.         Settlement Payment. Upon execution of this Agreement, by 5:00 PM on November 9, 2020, EMED shall pay TSAKALIDIS $36,413.
Upon payment, and by operation of this Agreement, TSAKALIDIS cancels and returns to EMED’s treasury the 87,869 shares of
common stock registered in his name in EMED’s Form S-1 registration statement.

 

2.2.         Release of All Claims. Except as provided for herein, and in further consideration of the mutual covenants hereto,
TSAKALIDIS agrees on behalf of him, and his respective successors, assigns, to irrevocably and unconditionally remises, releases,
acquits, satisfies and forever discharges EMED, specifically including its agents, directors, officers, affiliates, employees representatives,
insurance carriers, attorneys, divisions and subsidiaries, (and all agents, directors, officers, employees, representatives, insurance
carriers, and attorneys of such divisions and subsidiaries), and their predecessors, successors, administrators and assigns, and
all persons acting by, through, under, or in concert with any of them (collectively "Releases"), of and from any and
all claims, actions, causes of action, suits, debts, charges, complaints, claims, liabilities, obligations, promises, agreements,
controversies, damages, and expenses (including attorney fees and costs actually incurred), of any nature whatsoever, known or
unknown, in law or equity, arising out of the facts contained in the RECITALS.

 

2.3.         Except as for any specific rights created by virtue of this Agreement, TSAKALIDIS promises not to institute any future suits
or proceedings at law or in equity or any arbitration or administrative proceedings against EMED on account of any claim or cause
of action arising specifically out of the facts in the RECITALS herein.

 

2.4.         This is intended as a full and complete release and discharge of any or all claims that TSAKALIDIS may or might have or
had against each other regarding the facts in the RECITALS, and TSAKALIDIS does so in full and final settlement, release and discharge
of any and all such claims and the Parties intend to and does forever hereby release and discharge the each other of and from any
and all liability of any nature whatsoever for all damages to each other, specifically including, but not limited to, all past,
present and future rights to recover for sums of money compromised in this Agreement on account of said events alleged in the RECITALS,
as well as for all consequences, effects and results thereto and resulting damages to each other, whether the same or any circumstances
pertaining thereto are now known or unknown to TSAKALIDIS or anyone else, expected or unexpected by TSAKALIDIS or anyone else,
or have already appeared or developed or may now be latent or may in the future appear or develop or become known to TSAKALIDIS
or anyone else.

 

2.7        
  This Agreement constitutes a compromise, settlement, and release of disputed claims and is being entered into solely to
avoid the burden, inconvenience, and expense of litigating those claims. This Agreement is not to be and shall never be
construed or deemed an admission or concession by any of the Parties hereto of liability or culpability at any time for any
purpose concerning any claim being compromised, settled, and released, or any other matter.

 

		Section 3.	Miscellaneous Provisions.

 

3.1.         Notices. All notices, offers of other communications required or permitted to be given pursuant to this Agreement
shall be in writing and shall be considered as properly given or made (i) if delivered personally; or (ii) upon receipt by facsimile
transmission (with written confirmation of receipt) or confirmed electronic mail; or (iii) after the expiration of the second business
day following deposit with documented overnight delivery service; or (iv) five business days of transmission by regular mail. All
notices given or made pursuant hereto shall be so given or made to the parties at the following addresses:

 

	If to EMED: 	Electromedical Technologies, Inc.
	 	Attention: Mr. Matthew Wolfson
	 	16561 N. 92nd Street, Ste. 101
	 	Scottsdale, AZ 85260
	 	Telephone: 602-790-8034
	 	Email: ceo@electromedtech.com
	 	 
	If to TSAKALIDIS:	Iakovos Tsakalidis
	 	6940 E Doubletree Ranch Rd
	 	Paradise Valley, AZ, 85253
	 	Cell: 480 277 9679

 

The address of any party hereto may be changed by a notice
in writing given in accordance with the provisions hereof.

 

3.2.         Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, illegal
or unenforceable, such provision shall be severed and enforced to the extent possible or modified in such a way as to make it enforceable,
and the invalidity, illegality or unenforceability thereof shall not affect the validity, legality or enforceability of the remaining
provisions of this Agreement.

 

3.3.         Binding on Affiliated Third Parties. This Agreement shall inure to the benefit of and shall be binding upon EMED
and TSAKALIDIS and their respective agents, representatives, executors, administrators, trustees, personal representatives, partners,
directors, officers, shareholders, agents, attorneys, insurers, employees, representatives, predecessors, successors, heirs and
assigns.

 

3.4.         Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Arizona
without regard to principles of conflict of laws. Any controversy or claim arising out of or relating to this Settlement Agreement
or the Breach thereof, shall be settled by arbitration administered by the American Arbitration Association under its commercial
Arbitration Rules and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof.
The Arbitration shall be conducted in Scottsdale, AZ.

 

3.5.         Counterparts. This Agreement may be executed in multiple counterparts, all of which shall be deemed originals, and
with the same effect as if all Parties had signed the same document. All of such counterparts shall be construed together with
and shall constitute one Agreement, but in making proof, it shall only be necessary to produce one such counterpart. A facsimile
transmission shall be as valid and enforceable as an original.

 

    Page 2 of 3

     

    

 

3.6.         Entire Understanding. This Agreement is the entire, final, and complete agreement of the Parties relating to the
subject of this Agreement, and supersedes and replaces all prior or existing written and oral agreements between the Parties or
their representatives relating thereto.

 

3.7.         Further Assurances. The parties agree to execute and deliver to each other such other documents, and to do such other
acts and things, all as the other party may reasonably request for the purpose of carrying out the intent of this Agreement.

 

3.8.         Amendments. This Agreement shall not be amended or otherwise modified unless in writing signed by all of the parties
hereto.

 

3.9.         Acknowledgment. EMED and TSAKALIDIS acknowledges (i) They have read this Agreement and have consulted with their
respective attorneys concerning its contents and legal consequences and have requested any change in language necessary or desirable
to effectuate their intent and expectations so that the rule of construction of contracts construing ambiguities against the drafting
party shall be inapplicable; (ii) They have taken all corporate actions and obtained all corporate authorizations, consents and
approvals as are conditions precedent to their authority to execute this Agreement, and thus warrant that they are fully authorized
to bind the Party for which they execute this Agreement; and, (iii) There has been and will be no assignment or other transfer
of any claim released herein, or any part thereof, and each Party agrees to defend, indemnify and hold harmless the other party
from any claims, obligations, or other liabilities, including specifically attorney’s fees and costs incurred, which result
from the assertion by any third party of a right to any claim which is released by this Agreement. The foregoing warranties and
representations shall survive the execution and delivery of this Agreement.

 

3.10.       Assignment. This Agreement shall be binding upon and inure to the benefit of each party hereto or to such party's
heirs, executors, administrators, successors and assigns and nothing in this Agreement, express or implied, is intended to confer
upon any other person any rights or remedies of any nature whatsoever under or by reason of this Agreement.

 

3.11.       Confidentiality. Each of the parties represents and agrees that it will keep the terms, provisions and amounts in
this Agreement confidential and that it will not, without the consent of the other Party, disclose, divulge or furnish such confidential
information to any person other than their immediate families, their attorney and accountant (all of whom will be informed of and
bound by this confidentiality provision) except as required by law or, if necessary, to any applicable taxing authorities.

 

IN WITNESS WHEREOF,
the parties have signed this agreement upon the date first written above.

 

ELECTROMEDICAL
TECHNOLOGIES, INC.

 

 

	By:	                                      	 
	Name: MATTHEW WOLFSON	 
	Title: CEO, CFO	 
	 	 	 
	 	 	 
	Iakovos TSAKALIDIS 	 
	 	 	 
	 	 	 
	By:	 	 

 

    Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]